InflaRx (IFRX) Non-Current Assets (2016 - 2026)
InflaRx's (IFRX) quarterly Non-Current Assets came in at $1.7 million in Q1 2026, up 19.61% year-on-year from $1.5 million in Q1 2025, and down 5.12% quarter-over-quarter from $1.8 million in Q4 2025.
InflaRx (IFRX) Non-Current Assets (2016 - 2026) Analysis & Trends
InflaRx has disclosed Non-Current Assets across 11 years of filings, most recently posting $1.7 million for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $1.7 million, up 19.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (up 19.61% YoY), and the FY2025 annual result was $1.8 million, down 60.5% from the prior year.
- Non-Current Assets came in at $1.7 million for Q1 2026 at InflaRx, down from $1.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $22.6 million in Q2 2023 to a low of $1.5 million in Q1 2025.
- The 5-year median for Non-Current Assets is $4.5 million (2024), against an average of $6.0 million.
- Across the five-year window, Non-Current Assets tumbled 93.0% in 2022 and jumped 745.61% in 2023, its largest moves.
- InflaRx's Non-Current Assets stood at $5.1 million in 2022, then jumped by 127.04% to $11.6 million in 2023, then tumbled by 59.66% to $4.7 million in 2024, then tumbled by 60.5% to $1.8 million in 2025, then declined by 5.12% to $1.7 million in 2026.
- The last three Non-Current Assets figures came in at $1.7 million (Q1 2026), $1.8 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 62,953.78 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 39.71 Mn |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | 1.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.75 Mn |
| Dec 31, 2025 | 1.84 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 8.23 Mn |
| Mar 31, 2025 | 1.46 Mn |
| Dec 31, 2024 | 4.66 Mn |
| Sep 30, 2024 | 6.66 Mn |
| Jun 30, 2024 | 1.87 Mn |
| Mar 31, 2024 | 4.48 Mn |
| Dec 31, 2023 | 11.56 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 22.59 Mn |
| Mar 31, 2023 | 10.63 Mn |
| Dec 31, 2022 | 5.09 Mn |
| Sep 30, 2022 | 2.40 Mn |
| Jun 30, 2022 | 2.67 Mn |
| Mar 31, 2022 | 12.77 Mn |
| Dec 31, 2021 | 33.70 Mn |
| Sep 30, 2021 | 34.34 Mn |
| Jun 30, 2021 | 3.41 Mn |